Locomotion after spinal cord injury depends on constitutive activity in serotonin receptors.
Following spinal cord injury (SCI) neurons caudal to the injury are capable of rhythmic locomotor-related activity that can form the basis for substantial functional recovery of stepping despite the loss of crucial brain stem-derived neuromodulators like serotonin (5-HT). Here we investigated the contribution of constitutive 5-HT(2) receptor activity (activity in the absence of 5-HT) to locomotion after SCI. We used a staggered hemisection injury model in rats to study this because these rats showed a robust recovery of locomotor function and yet a loss of most descending axons. Immunolabeling for 5-HT showed little remaining 5-HT below the injury, and locomotor ability was not correlated with the amount of residual 5-HT. Furthermore, blocking 5-HT(2) receptors with an intrathecal (IT) application of the neutral antagonist SB242084 did not affect locomotion (locomotor score and kinematics were unaffected), further indicating that residual 5-HT below the injury did not contribute to generation of locomotion. As a positive control, we found that the same application of SB242084 completely antagonized the muscle activity induced by exogenous application of the 5-HT(2) receptor agonists alpha-methyl-5-HT (IT). In contrast, blocking constitutive 5-HT(2) receptor activity with the potent inverse agonist SB206553 (IT) severely impaired stepping as assessed with kinematic recordings, eliminating most hindlimb weight support and overall reducing the locomotor score in both hind legs. However, even in the most severely impaired animals, rhythmic sweeping movements of the hindlimb feet were still visible during forelimb locomotion, suggesting that SB206553 did not completely eliminate locomotor drive to the motoneurons or motoneuron excitability. The same application of SB206553 had no affect on stepping in normal rats. Thus while normal rats can compensate for loss of 5-HT(2) receptor activity, after severe spinal cord injury rats require constitutive activity in these 5-HT(2) receptors to produce locomotion.
Fouad
K
K
Centre for Neuroscience, Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.
Rank
M M
MM
Vavrek
R
R
Murray
K C
KC
Sanelli
L
L
Bennett
D J
DJ
D000631:Aminopyridines / Q000494:pharmacology; D000818:Animals; D002818:Cordotomy; D004576:Electromyography; D005260:Female; D020233:Gait Disorders, Neurologic / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D006614:Hindlimb / Q000503:physiopathology; D007211:Indoles / Q000494:pharmacology; D007278:Injections, Spinal; D008124:Locomotion / Q000187:drug effects / Q000502:physiology*; D009123:Muscle Hypotonia / Q000209:etiology; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D044348:Receptors, Serotonin, 5-HT2 / Q000502:physiology*; D020127:Recovery of Function; D012701:Serotonin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use; D058830:Serotonin 5-HT2 Receptor Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use; D013119:Spinal Cord Injuries / Q000150:complications / Q000503:physiopathology*; D013623:Tail / Q000503:physiopathology
C107820:6-chloro-5-methyl-1-((2-(2-methylpyrid-3-yloxy)pyrid-5-yl)carbamoyl)indoline; D000631:Aminopyridines; D007211:Indoles; D011725:Pyridines; D044348:Receptors, Serotonin, 5-HT2; D058830:Serotonin 5-HT2 Receptor Antagonists; D017366:Serotonin Receptor Agonists; C042390:alpha-methylserotonin; D012701:Serotonin; C094868:SB 206553